Karuna Therapeutics KRTX signed a definitive merger agreement with Bristol Myers Squibb BMY. Per the agreement terms, Bristol Myers will acquire all outstanding shares of Karuna for $330 per share in ...

Neurological drugs developer Karuna Therapeutics is building up its pipeline with a pair of molecules initially developed for kidney disorders. It’s a small bet that could pay off in a big way by ...

Read full article: Walgreens to pay up to $350 million in opioid settlement, includes whistleblower compensation JSO drug evidence from a raid on a home in the Arlington area. FILE - In this June 15, ...

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer’s drugmaker Karuna Therapeutics for $14 billion. Bristol Myers said it would pay $330 a share cash for ...

Karuna Therapeutics KRTX announced the submission of a new drug application (“NDA”) with the FDA seeking approval for its lead candidate KarXT, as a potential treatment of schizophrenia. If approved, ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (“Karuna,” formerly Karuna Pharmaceuticals), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders ...

The Karuna Health Foundation has filed a development application for its weed shop at 3636 West 4 th Avenue. The store is one of two Vancouver locations by the business, the other being at 4510 ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (“Karuna”) focused on targeting muscarinic receptors for the treatment of neuropsychiatric disorders, including psychosis in schizophrenia, psychosis ...